Literature DB >> 16562709

Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB.

M L Rich1, A R Socci, C D Mitnick, E A Nardell, M C Becerra, C Bonilla, J Bayona, K J Seung, J Furin, P E Farmer, J S Mukherjee.   

Abstract

BACKGROUND: There is no gold standard on how national tuberculosis programs should design retreatment regimens. Often drug susceptibility testing (DST) is not available for all patients, and representative DST patterns in patient populations are used to guide therapy.
OBJECTIVES: To examine DST patterns in different patient populations based on previous treatment and to estimate the number of effective anti-tuberculosis agents in several retreatment regimens.
METHODS: We reviewed DST results from patients treated with individualized regimens in Peru between January 1998 and July 2004. We stratified patients into four groups based on previous treatment exposure from Group 1 who had failed only one regimen to Group 4 who had failed three regimens. We compared resistance frequencies across the four groups. In Groups 1 and 3, the number of likely effective agents under six possible retreatment regimen scenarios was estimated.
RESULTS: Resistance to second-line drugs was significantly higher in groups with more previous courses of treatment. A few retreatment regimens could be identified that would allow at least 80% of patients to receive at least four likely effective drugs.
CONCLUSION: Because it is associated with resistance frequencies, previous treatment exposure can serve to guide the design of non-individualized MDR-TB regimens.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16562709

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  6 in total

1.  Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence.

Authors:  Molly F Franke; Sasha C Appleton; Carole D Mitnick; Jennifer J Furin; Jaime Bayona; Katiuska Chalco; Sonya Shin; Megan Murray; Mercedes C Becerra
Journal:  Clin Infect Dis       Date:  2012-12-07       Impact factor: 9.079

Review 2.  Epidemiology and treatment of multidrug resistant tuberculosis.

Authors:  Carole D Mitnick; Sasha C Appleton; Sonya S Shin
Journal:  Semin Respir Crit Care Med       Date:  2008-09-22       Impact factor: 3.119

3.  Comprehensive treatment of extensively drug-resistant tuberculosis.

Authors:  Carole D Mitnick; Sonya S Shin; Kwonjune J Seung; Michael L Rich; Sidney S Atwood; Jennifer J Furin; Garrett M Fitzmaurice; Felix A Alcantara Viru; Sasha C Appleton; Jaime N Bayona; Cesar A Bonilla; Katiuska Chalco; Sharon Choi; Molly F Franke; Hamish S F Fraser; Dalia Guerra; Rocio M Hurtado; Darius Jazayeri; Keith Joseph; Karim Llaro; Lorena Mestanza; Joia S Mukherjee; Maribel Muñoz; Eda Palacios; Epifanio Sanchez; Alexander Sloutsky; Mercedes C Becerra
Journal:  N Engl J Med       Date:  2008-08-07       Impact factor: 91.245

4.  Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa.

Authors:  Kwonjune J Seung; David B Omatayo; Salmaan Keshavjee; Jennifer J Furin; Paul E Farmer; Hind Satti
Journal:  PLoS One       Date:  2009-09-25       Impact factor: 3.240

5.  Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality.

Authors:  Carole D Mitnick; Molly F Franke; Michael L Rich; Felix A Alcantara Viru; Sasha C Appleton; Sidney S Atwood; Jaime N Bayona; Cesar A Bonilla; Katiuska Chalco; Hamish S F Fraser; Jennifer J Furin; Dalia Guerra; Rocio M Hurtado; Keith Joseph; Karim Llaro; Lorena Mestanza; Joia S Mukherjee; Maribel Muñoz; Eda Palacios; Epifanio Sanchez; Kwonjune J Seung; Sonya S Shin; Alexander Sloutsky; Arielle W Tolman; Mercedes C Becerra
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

6.  Impact of Infection Control Measures to Control an Outbreak of Multidrug-Resistant Tuberculosis in a Human Immunodeficiency Virus Ward, Peru.

Authors:  Eduardo Ticona; Luz Huaroto; Daniela E Kirwan; Milagros Chumpitaz; César V Munayco; Mónica Maguiña; Marco A Tovar; Carlton A Evans; Roderick Escombe; Robert H Gilman
Journal:  Am J Trop Med Hyg       Date:  2016-09-12       Impact factor: 2.345

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.